Tennessee Senate Bill SB2323

Tennessee 2025-2026 Regular Session

• Introduced: 2/2/26
• Chaptered: 5/5/26
• Passed: 5/5/26

Caption

AN ACT to amend Tennessee Code Annotated, Title 39, Chapter 17, Part 4, relative to drugs.

Summary

SB2323 amends Tennessee’s controlled-substance precursor law governing the sale of pseudoephedrine and ephedrine products. The bill updates statutory references from NPLEx and NADDI to the state’s “electronic sales tracking system,” clarifies that pharmacist-generated prescription orders are covered, and removes language that had expressly required pharmacists or interns to counsel purchasers and allowed them to refuse a sale based on their judgment of legitimacy. The bill also expands and modernizes the tracking framework. It requires pharmacies to use the electronic sales tracking system for real-time reporting of over-the-counter pseudoephedrine/ephedrine sales, provides liability protections for pharmacies acting without negligence or misconduct, and limits use of the data to law enforcement, healthcare professionals, and pharmacists for controlling methamphetamine precursor sales. If the current system is unavailable, pharmacies must switch to Tennessee Methamphetamine Information System (TMIS) when free access is provided. Beginning in 2027, manufacturers of ephedrine or pseudoephedrine products sold in Tennessee must pay monthly fees to support the system, subject to annual fee-setting limits. The bill also strengthens registry-based restrictions and adds rules for online and remote sales. The Tennessee Bureau of Investigation must notify the system administrator at least weekly about people placed on or removed from the methamphetamine registry, and the system must generate stop-sale alerts for listed individuals. For remote transactions, sellers must verify government-issued identification, confirm the purchaser’s identity and residential address through the tracking system, and ensure the sale does not exceed daily, 30-day, or yearly limits. Products may only be shipped to the residential address on the ID, not to P.O. boxes or commercial mail receiving agencies. Overall, the bill appears aimed at tightening enforcement against methamphetamine precursor diversion while preserving access for legitimate purchasers and pharmacies. The committee vote reflected strong support, with the Senate Judiciary Committee recommending passage 8-0. No committee transcript was provided, so there is no recorded floor or committee debate to indicate opposition, but the main policy tensions inherent in the bill are between stronger anti-diversion controls and the administrative burden on pharmacies and sellers, especially for online sales and fee-funded system maintenance.

Impact

SB2323 would amend Tennessee Code Annotated § 39-17-431 and related provisions governing the sale and tracking of pseudoephedrine and ephedrine, replacing references to NPLEx and NADDI with the state’s electronic sales tracking system and administrator. It would also add new requirements for remote sales verification, registry notifications, stop-sale alerts, manufacturer fee assessments beginning in 2027, and pharmacy liability protections, thereby affecting pharmacies, retailers, manufacturers, law enforcement, and purchasers of methamphetamine precursor products.

Sentiment

The available voting history suggests broad support for the bill, as the Senate Judiciary Committee recommended passage unanimously, 8-0. The bill’s structure indicates a generally pro-enforcement, anti-diversion policy approach, with no recorded committee transcript showing substantive opposition. The absence of recorded debate makes it difficult to identify detailed public sentiment, but the committee action suggests the measure was viewed favorably and as a technical-and-policy update to existing precursor-control law.

Contention

The main points of contention likely concern the balance between preventing methamphetamine precursor diversion and maintaining practical access for legitimate consumers and pharmacies. Potential concerns include the removal of explicit pharmacist counseling/refusal language, the operational burden of real-time reporting and identity verification for remote sales, the scope of data access, and the new manufacturer fee structure. Pharmacies and sellers may be sensitive to compliance costs and liability issues, while law enforcement and public-safety advocates are likely to support the tighter controls and registry-based stop-sale system.